JO3197B1 - (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان - Google Patents

(مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان

Info

Publication number
JO3197B1
JO3197B1 JOP/2010/0107A JOP20100107A JO3197B1 JO 3197 B1 JO3197 B1 JO 3197B1 JO P20100107 A JOP20100107 A JO P20100107A JO 3197 B1 JO3197 B1 JO 3197B1
Authority
JO
Jordan
Prior art keywords
diazepin
ribofuranosyl
deoxy
tetrahydro
derivatives
Prior art date
Application number
JOP/2010/0107A
Other languages
English (en)
Inventor
Duvall Bridget
Hamilton Gregory
Ferraris Dana
Belyakov Sergei
Vaal Mark
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3197B1 publication Critical patent/JO3197B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

.يتم في الطلب الحالي تقديم المركبات المستخدمة لتثبيط انزيم نزع المجموعة الأمينية المسئول عن تثبيط نشاط المركبات العلاجية , وطرق استخدامها.
JOP/2010/0107A 2009-04-06 2010-04-06 (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان JO3197B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16711209P 2009-04-06 2009-04-06

Publications (1)

Publication Number Publication Date
JO3197B1 true JO3197B1 (ar) 2018-03-08

Family

ID=42126083

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2010/0107A JO3197B1 (ar) 2009-04-06 2010-04-06 (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان

Country Status (10)

Country Link
US (1) US8324180B2 (ar)
EP (1) EP2417146B1 (ar)
JP (1) JP5687687B2 (ar)
AR (1) AR076262A1 (ar)
AU (2) AU2010234637B2 (ar)
CA (1) CA2757743C (ar)
ES (1) ES2593088T3 (ar)
JO (1) JO3197B1 (ar)
TW (1) TWI477508B (ar)
WO (1) WO2010118006A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2778B1 (ar) * 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
US8609631B2 (en) 2009-04-06 2013-12-17 Eisai Inc. Compositions and methods for treating cancer
ES2628609T3 (es) * 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4017606A (en) 1973-10-04 1977-04-12 The Upjohn Company Organic compounds and process
US4275057A (en) * 1980-01-28 1981-06-23 The United States Of America As Represented By The Department Of Health, Education And Welfare Seven-membered ring compounds as inhibitors of cytidine deaminase
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
JPS61500224A (ja) 1983-10-26 1986-02-06 グリ−ル、シエルダン　ビ− 腫瘍性組織を放射線に対して増感する医薬組成物
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US4965374A (en) 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1992018517A1 (en) 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
FR2682112B1 (fr) 1991-10-08 1993-12-10 Commissariat A Energie Atomique Procede de synthese d'acide ribonucleique (arn) utilisant un nouveau reactif de deprotection.
US5594124A (en) 1992-06-22 1997-01-14 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2',2'-difluoropyrimidine nucleosides and 2'-deoxy-2'-fluoropyrimidine nucleosides and intermediates thereof
US5371210A (en) 1992-06-22 1994-12-06 Eli Lilly And Company Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5821357A (en) 1992-06-22 1998-10-13 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides
US5606048A (en) 1992-06-22 1997-02-25 Eli Lilly And Company Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
US5426183A (en) 1992-06-22 1995-06-20 Eli Lilly And Company Catalytic stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides
WO1994019362A1 (en) 1993-02-23 1994-09-01 City Of Hope 4-ethoxy 5-fluoro 2'deoxyuridine
WO1994026761A1 (en) 1993-05-14 1994-11-24 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB9311252D0 (en) 1993-06-01 1993-07-21 Hafslund Nycomed As Cell growth regualtors
US5637688A (en) 1994-12-13 1997-06-10 Eli Lilly And Company Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride
US5521294A (en) 1995-01-18 1996-05-28 Eli Lilly And Company 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides
US6001994A (en) 1995-12-13 1999-12-14 Eli Lilly And Company Process for making gemcitabine hydrochloride
US5760208A (en) 1996-08-14 1998-06-02 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Process to prepare pyrimidine nucleosides
TW466112B (en) 1998-04-14 2001-12-01 Lilly Co Eli Novel use of 2'-deoxy-2',2'-difluorocytidine for immunosuppressive therapy and pharmaceutical composition comprising the same
PL348673A1 (en) 1998-09-25 2002-06-03 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
US6933287B1 (en) 1999-03-01 2005-08-23 Sheldon B. Greer Dramatic simplification of a method to treat neoplastic disease by radiation
AU3354500A (en) 1999-03-01 2000-09-21 Halogenetics, Inc. Dramatic simplification of a method to treat neoplastic disease by radiation
US6462191B1 (en) 2000-07-13 2002-10-08 Air Products And Chemicals, Inc. Synthesis of 2-deoxy-2-fluoro-arabinose derivatives
EP1348712B1 (en) 2000-11-29 2011-05-04 Mitsui Chemicals, Inc. Processes and intermediates in the synthesis of L-thymidine
WO2002056912A2 (en) 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
EP2322534A1 (en) 2001-05-18 2011-05-18 Rakesh Kumar Antiviral nucleosides
AU2003278904A1 (en) 2002-09-24 2004-04-19 Kornis Pharmaceuticals, Incorporated 1, 3, 5-triazines for treatment of viral diseases
WO2005115410A2 (en) 2004-05-06 2005-12-08 University Of Rochester Context dependent inhibitors of cytidine deaminases and uses thereof
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
CN101076536A (zh) 2004-07-30 2007-11-21 药华医药股份有限公司 β－核苷的立体选择性合成
CN101076535A (zh) 2004-12-08 2007-11-21 西科尔公司 二氟核苷及其制备方法
US20080080163A1 (en) 2006-09-29 2008-04-03 Grote Industries, Inc. Illuminated devices utilizing light active sheet material with integrated light emitting diode (LED), methods of producing illuminated devices, and kits therefor
WO2008085611A2 (en) * 2006-11-27 2008-07-17 University Of Miami Designer theraphy of pancreatic tumors
WO2009021551A1 (en) 2007-08-13 2009-02-19 Universite De La Mediterranee A method for assessing the risk of toxicity in a chemotherapy
JO2778B1 (ar) 2007-10-16 2014-03-15 ايساي انك مركبات وتركيبات وطرق معينة
WO2010047698A1 (en) 2008-10-22 2010-04-29 University Of Alabama At Birmingham Activation-induced cytidine deaminase inhibitor suppression of autoimmune diseases
ES2628609T3 (es) 2009-04-06 2017-08-03 Otsuka Pharmaceutical Co., Ltd. Combinación de fármacos antineoplásicos a base de citidina con inhibidor de citidina deaminasa y uso del mismo en el tratamiento de cáncer
JP5730854B2 (ja) * 2009-04-06 2015-06-10 大塚製薬株式会社 デシタビンとシチジンデアミナーゼ阻害剤との組合せ、およびがんの治療におけるその使用

Also Published As

Publication number Publication date
TWI477508B (zh) 2015-03-21
AU2016213881A1 (en) 2016-09-01
CA2757743C (en) 2017-10-10
AU2010234637A1 (en) 2011-11-10
CA2757743A1 (en) 2010-10-14
WO2010118006A1 (en) 2010-10-14
AU2016213881B2 (en) 2018-03-22
US8324180B2 (en) 2012-12-04
EP2417146A1 (en) 2012-02-15
JP5687687B2 (ja) 2015-03-18
ES2593088T3 (es) 2016-12-05
TW201102397A (en) 2011-01-16
JP2012522840A (ja) 2012-09-27
AU2010234637B2 (en) 2016-05-12
EP2417146B1 (en) 2016-07-13
US20100279966A1 (en) 2010-11-04
AR076262A1 (es) 2011-06-01

Similar Documents

Publication Publication Date Title
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
UA107667C2 (uk) Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку
MX2010001218A (es) Metodos y composiciones para tratamiento contra esquizofrenia mediante uso de terapia combinada de agentes antipsicoticos.
UA106367C2 (uk) Похідні азадиспіро[3.0.4.1]декану та їх застосування
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MX2009012623A (es) Moduladores de cinasa heterociclicos.
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
MX2011007930A (es) Conjugados de insulina cristalina.
PL2231636T3 (pl) Pochodne pirazolowe i ich zastosowanie jako inhibitorów kinaz zależnych od cyklin
MX2012003539A (es) Derivados de indol como moduladores de los canales de calcio activados por la liberacion de calcio (crac).
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
UA98629C2 (ru) Соединения и способ модуляции киназ
MX2010000465A (es) Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
JO3134B1 (ar) مثبطات نشاط akt
MX2009009117A (es) Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
TNSN08400A1 (en) Organic compounds and their uses
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
ZA201000314B (en) 2, 3-dihydrobenzo[1, 4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL191763A0 (en) Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators
IL191751A0 (en) Pyrrolo[2,3-c]pyridine derivatives
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
JO3262B1 (ar) توليفة من ديسيتابين مع مثبط سيتيدين دي أميناز واستخدامها في علاج السرطان